The re-emergence of the 4 plus 7 expansion varieties involves Entikawe, Atavastatin, Montiol scatter:

On June 4, the Yunnan Provincial Medical Insurance Bureau issued a letter from the Yunnan Medical Security Bureau on the submission of a written statement of information and a list of production capacityThe documents show a shortage of eight varieties of the 4 plus 7 expansion, namely, enticave dispersal tablets, attovastatin calcium tablets, lipasterone tablets, Malayacid inapis tablets, benzodiazepines, ebeceatan tablets, cephalosporine tablets, and monitesManufacturers corresponding to Suzhou Dongrui, Xing'an Pharmaceuticals, Changzhou Four Pharmaceuticals, Yangzijiang Pharmaceutical Group Jiangsu Pharmaceuticals, National Pharmaceutical Group Rongsheng Pharmaceuticals, Hanyu Pharmaceuticals, Guangzhou Baiyunshan Tianxin Pharmaceuticals, Hunan Warner Pharmaceutical Stakesdocument pointed out that in the process of monitoring the procurement of drugs by the state, it was found that some of the selected enterprises failed to supply the selected drugs in a timely manner in accordance with hospital demand, according to which the Yunnan Provincial Medical Insurance Bureau required the relevant pharmaceutical manufacturers to submit written instructions and production capacity lists that could not be supplied normally, stamped with the company's official seal and submitted to the Yunnan Medical Security Bureau Price Recruitment Office before June 1, if there is no reasonable reason, Yunnan will, in accordance with the relevant provisions, the supply situation into the province's medical insurance credit supervision records and report to the State Joint Management, and in accordance with the provisions of the replacement of the relevant drugs, to ensure the hospital's drug supplyThis is not the first timea shortage of medicines collected across the countryOn April 10,, Shanghai Sunshine Pharmaceutical Procurement Network released "Shanghai's work tips on the implementation of the results of the second batch of state-organized drug centralized procurement (2)." Affected by the outbreak, 4 plus 7 expanded 32 varieties, omesatin ester tablets, Amison tan tablets, polyglycol 4000 loose, hydrochloric acid left sitlily tablets four varieties may be in the early stages of implementation of the supply of tight, delivery delays and other issues, including omethatinester is expected to gradually resume production capacity in June, normal supplyThe manufacturers involved are Huahai Pharmaceuticals, Dongsun Pharmaceuticals, Hunan Warner Pharmaceutical Stakes and Hunan Jiuxian Pharmaceuticalsand this year due to the impact of the outbreak, for the amount of procurement varieties temporarily unable to supply, in the relevant documents the state to give enterprises a buffer period, allowing as long as the resumption of supply in June can be.